Sepantronium hydrochloride
Based on 22 publication(s) in Google Scholar
Sepantronium hydrochloride (YM-155 hydrochloride) is a novel survivin suppressant with an IC50 of 0.54 nM for the inhibition of survivin promoter activity.
For research use only. We do not sell to patients.
- CAS No.: 355406-09-6
- Formula: C20H19ClN4O3
- Molecular Weight:398.84
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sepantronium hydrochloride
More- Adv Sci (Weinh). 2025 Feb 4:e2409769. [Abstract]
- Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]
- Cell Death Dis. 2020 Nov 15;11(11):982. [Abstract]
- Stem Cell Res Ther. 2020 Jun 10;11(1):229. [Abstract]
- Biochem Pharmacol. 2024 Jun:224:116242. [Abstract]
- Drug Deliv Transl Res. 2025 Oct 29. [Abstract]
- Mol Cancer Ther. 2025 Apr 28:OF1-OF13. [Abstract]
- Nutrients. 2018 Mar 15;10(3). pii: E353. [Abstract]
- Int Immunopharmacol. 2026 Apr 15:175:116421. [Abstract]
- Cancers (Basel). 2024 Sep 5;16(17):3090. [Abstract]
- Cancers. 2019 Oct 14;11(10):1550. [Abstract]
- Cancers. 2019 Jul 5;11(7):947. [Abstract]
- Sci Rep. 2019 Aug 21;9(1):12149. [Abstract]
- BMC Complement Med Ther. 2020 Sep 3;20(1):269. [Abstract]
- Toxicol Appl Pharmacol. 2020 Apr 17;397:115013. [Abstract]
- Cancer Res Commun. 2025 Jun 1;5(6):1034-1048. [Abstract]
- Anticancer Res. 2019 Sep;39(9):4817-4828. [Abstract]
- Anticancer Res. 2019 Feb;39(2):609-617. [Abstract]
- Anticancer Res. 2018 Dec;38(12):6699-6706. [Abstract]
- bioRxiv. 2024 Aug 6:2024.03.21.586169. [Abstract]
- Res Sq. 2023 Dec 23:rs.3.rs-3770403. [Abstract]
- Research Square Preprint. 2021 Jul.
Customer Validation & Images
-
WB
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
IHC
Biological Activity
IC50: 0.54 nM (survivin)
Sepantronium bromide (YM155; 30 μM) is not sensitive to survivn gene promoter-driven luciferase reporter activity. Sepantronium bromide shows significant supression on endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 via transcriptional inhibition of the survivin gene promoter. Sepantronium bromide (100 nM) does not affect protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin. Sepantronium bromide potently inhibits human cancer cell lines (mutated or truncated p53) such as PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50s ranging from 2.3 to 11 nM, respectively[1].
Sepantronium bromide (YM155) resultin in an increase in sensitivity of NSCLC cells to γ-radiation. Sepantronium bromide combined with γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. In addition, Sepantronium bromide delays the repair of radiation-induced double-strand breaks in nuclear DNA[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Sepantronium bromide (YM155) in combination with γ-radiation shows potent antitumor activity against H460 or Calu6 xenografts in nude mice[2].
In this orthotopic renal and metastatic lung tumors models, Sepantronium bromide (YM-155) and IL-2 additively decreases tumor weight, lung metastasis, and luciferin-stained tumor images[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 355406-09-6
-
Appearance Solid
-
Molecular Weight 398.84
-
Formula C20H19ClN4O3
-
Color Light brown to brown
-
SMILES
O=C(C1=C2[N+](CC3=NC=CN=C3)=C(C)N1CCOC)C4=C(C=CC=C4)C2=O.[Cl-]
-
Synonyms
YM-155 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Chromosome Missegregation Triggers Tumor Cell Pyroptosis and Enhances Anti-Tumor Immunotherapy in Colorectal Cancer. [Abstract]2025 Feb 4:e2409769. PMID: 39903759 -
Cancer Lett
Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinoma. [Abstract]2018 Jul 1:425:54-64. PMID: 29608986
Sepantronium hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]
The cell model HepG2-Sur5P-EGFP-Sur3U was treated with Sepantronium bromide (YM155) at a final concentration of 100 nmol/ml. After 24 h later, the fluorescence strength of EGFP was recorded and the expression of Survivin was examined.
Sepantronium hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]
Huh-7 cell xenograft models were established by subcutaneously injection of 1 × 106 cells per mouse in 4 groups of nude mice (n = 5/group). After five intratumoral injections of Sepantronium bromide (YM155) at 3 mg/ml, the tumor volume was counted weekly.
Sepantronium hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]
Huh-7 cell xenograft models were established by subcutaneously injection of 1 × 106. cells per mouse in 4 groups of nude mice (n = 5/group). After five intratumoral injections of Sepantronium bromide (YM155) at 3 mg/ml. The xenografted tumors were weighed and compared.
Sepantronium hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Jul 1:425:54-64. [Abstract]
Sepantronium bromide (YM-155, 3mg/mL)The xenograft tumor sections were examined by immunohistochemistry and TUNEL labeling. The expression levels of Survivin and the percentages of apoptotic cells in xenografted tumors were quantified within 5 high-power fields under microscope and showed in histograms.
-
Cell Death Dis
A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factors. [Abstract]2020 Nov 15;11(11):982. PMID: 33191401 -
Stem Cell Res Ther
Pulp stem cells with hepatocyte growth factor overexpression exhibit dual effects in rheumatoid arthritis. [Abstract]2020 Jun 10;11(1):229. PMID: 32522231 -
Biochem Pharmacol
ONC212 enhances YM155 cytotoxicity by triggering SLC35F2 expression and NOXA-dependent MCL1 degradation in acute myeloid leukemia cells. [Abstract]2024 Jun:224:116242. PMID: 38679209 -
Drug Deliv Transl Res
Leveraging quantum chemical properties in transfer learning for predicting blood-brain barrier permeability of drugs. [Abstract]2025 Oct 29. PMID: 41160380 -
Mol Cancer Ther
Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. [Abstract]2025 Apr 28:OF1-OF13. PMID: 40293279 -
Nutrients
Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis. [Abstract]2018 Mar 15;10(3). pii: E353. PMID: 29543705
Sepantronium hydrochloride purchased from MedChemExpress. Usage Cited in: Nutrients. 2018 Mar 15;10(3). pii: E353. [Abstract]
Influences of YM155, a chemical inhibitor of survivin on ABT-737-induced apoptosis are analyzed by western blot.
-
Int Immunopharmacol
A multi-omics R-loop-linked risk program highlights CKS2-positive proliferative tumor cells as drivers of glioma growth. [Abstract]2026 Apr 15:175:116421. PMID: 41763168 -
Cancers (Basel)
Molecular Insights into the Anticancer Activity of Withaferin-A: The Inhibition of Survivin Signaling. [Abstract]2024 Sep 5;16(17):3090. PMID: 39272948 -
Cancers
Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs. [Abstract]2019 Oct 14;11(10):1550. PMID: 31614999 -
Cancers
Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. [Abstract]2019 Jul 5;11(7):947. PMID: 31284441 -
Sci Rep
Extracorporeal shock waves protect cardiomyocytes from doxorubicin-induced cardiomyopathy by upregulating survivin via the integrin-ILK-Akt-Sp1/p53 axis. [Abstract]2019 Aug 21;9(1):12149. PMID: 31434946 -
BMC Complement Med Ther
Myricanol 5-fluorobenzyloxy ether regulation of survivin pathway inhibits human lung adenocarcinoma A549 cells growth in vitro. [Abstract]2020 Sep 3;20(1):269. PMID: 32883260 -
Toxicol Appl Pharmacol
Arsenic trioxide-induced p38 MAPK and Akt mediated MCL1 downregulation causes apoptosis of BCR-ABL1-positive leukemia cells. [Abstract]2020 Apr 17;397:115013. PMID: 32305283 -
Cancer Res Commun
Histone Deacetylase Inhibitors Target DNA Replication Regulators and Replication Stress in Ewing Sarcoma Cells. [Abstract]2025 Jun 1;5(6):1034-1048. PMID: 40478628 -
Anticancer Res
Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer. [Abstract]2019 Sep;39(9):4817-4828. PMID: 31519584 -
Anticancer Res
2019 Feb;39(2):609-617. PMID: 30711936
Sepantronium hydrochloride purchased from MedChemExpress. Usage Cited in: Anticancer Res. 2019 Feb;39(2):609-617. [Abstract]
A2780 CSLCs are treated in the presence or absence of AS602801 (7.5 μM) and/or YM155 (10 nM) for 3 days, and then subjected to western blot analysis of survivin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
-
Anticancer Res
AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel. [Abstract]2018 Dec;38(12):6699-6706. PMID: 30504379 -
bioRxiv
2024 Aug 6:2024.03.21.586169. PMID: 38586030 -
Res Sq
Targeting mTOR and Survivin Concurrently Potentiates Radiation Therapy in Renal Cell Carcinoma by Suppressing DNA Damage Repair and Amplifying Mitotic Catastrophe. [Abstract]2023 Dec 23:rs.3.rs-3770403. PMID: 38196607 -
Protocol
The antiproliferative activity of Sepantronium bromide is measured. After treatment with Sepantronium bromide for 48 h, the cell count is determined by sulforhodamine B assay. The GI50 value is calculated by logistic analysis, which is the drug concentration resulting in a 50% reduction in the net protein increase (as measured by sulforhodamine B staining) in control cells during the drug incubation. The assay is done in triplicate, and the mean GI50 value is obtained from the results of four independent assays.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Five-week-old male nude mice (BALB/c nu/nu) are used for the assay. PC-3 cells (2×106-3×106) are injected into the flanks of the mice and allowed to reach a tumor volume of > 100 mm3 in tumor volume (length×width2×0.5). Sepantronium bromide is s.c. administered as a 3-day continuous infusion per week for 2 weeks using an implanted micro-osmotic pump or i.v. administered five times a week for 2 weeks. The percentage of tumor growth inhibition 14 days after initial Sepantronium bromide administration is calculated for each group using the following formula: MTV=100×{1-[(MTV of the treated group on day 14)-(MTV of the treated group on day 0)]/[(MTV of the control group on day 14)-(MTV of the control group on day 0)]}, where MTV is mean tumor volume. For both the frozen tumors and plasma samples, survivin expression levels are analyzed by Western blotting and Sepantronium bromide concentration by high-performance liquid chromatography/triple quadrupole mass spectrometry (LC/MS/MS) using validated methods.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
References
[1]. Nakahara T, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007 Sep 1;67(17):8014-21. [Content Brief]
[2]. Iisa T, et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res. 2008 Oct 15;14(20):6496-504. [Content Brief]
[3]. Guo K, et al. A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model. Oncotarget. 2015 Aug 28;6(25):21137-47. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz